Ustekinumab in Crohn's disease: evidence to date and place in therapy.
Article Details
- CitationCopy to clipboard
Engel T, Kopylov U
Ustekinumab in Crohn's disease: evidence to date and place in therapy.
Ther Adv Chronic Dis. 2016 Jul;7(4):208-14. doi: 10.1177/2040622316653306. Epub 2016 Jul 6.
- PubMed ID
- 27433311 [ View in PubMed]
- Abstract
Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ustekinumab Interleukin-23 (Protein Group) Protein group Humans YesInhibitorDetails